Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Diantini, Ajeng
- The Impact of Diabetes Distress on the Treatment Outcome
Abstract Views :157 |
PDF Views:0
Authors
Dyah Aryani Perwitasari
1,
Imaniar Noor Faridah
1,
Woro Supadmi
1,
Mentari Yulistika
2,
Sitti Nurdjaja Soltief
3,
Elfride Irawati Sianturi
4,
Nurul Masyitoh
5,
Ajeng Diantini
6
Affiliations
1 University of Ahmad Dahlan, Yogyakarta, ID
2 RSUD Panembahan Senopati Bantul, Yogyakarta, ID
3 RSUD DOK II Jayapura, ID
4 University of Cendrawasih, Jayapura, ID
5 RSUD Dr. Abdul Aziz Singkawang, ID
6 University of Padjajaran, Bandung, ID
1 University of Ahmad Dahlan, Yogyakarta, ID
2 RSUD Panembahan Senopati Bantul, Yogyakarta, ID
3 RSUD DOK II Jayapura, ID
4 University of Cendrawasih, Jayapura, ID
5 RSUD Dr. Abdul Aziz Singkawang, ID
6 University of Padjajaran, Bandung, ID
Source
Research Journal of Pharmacy and Technology, Vol 12, No 1 (2019), Pagination: 223-226Abstract
Objective. The prevalence of diabetes mellitus is getting increased in Indonesia. The treatment and disease complexity may cause patients distress. The objective of this study is to determine the association between diabetes-related distress and the treatment outcome of T2D patients. Methods. This study used a cross-sectional design. Data were collected from diabetes patients at Abdul Azis Hospital, Singkawang, Meranti Hospital, Meranti County and DOK II Hospital Jayapura during 2017 and 2018. The inclusion criteria were patients diagnosed with T2DM, aged over 18, and under outpatient treatment at the hospitals in the aforementioned period. The clinical and socio-demographic data were taken from the patients’ medical record. The Diabetes- Distress Scale (DDS) was used to measures the patients’ distress. Results. The patient characteristic of this research showed that the mean of patients’age was 57.14 years old (SD = 9.4). Almost 59% among them was female, 92.6% was married, and 62.2% had a higher level of education. Around 54% of patients had a HbA1C of more than 7.5 with a mean 8.68 (SD=2.58). It also showed from the plasma glucose which 53% had more than 200 mg/dL (the average 219.64 (SD=85.11)), and 71% had 2-hours postprandial more than 200mg/dL. The significant associations were seen between all domains of distress and random blood glucose (p<0.05). The emotional and management related distress had the significant association with HbA1C (p<0.05). Conclusion. All the distress domains are related to the high level of random blood glucose. Furthermore, the emotional and management related distress is related with the HbA1C. The combination between pharmacological and psychological intervention is suggested to improve the clinical outcome.Keywords
Distress, Diabetes, Glycemic, Control, Indonesia.References
- Health M of. Basic Health Research. 2013 2013. http://labmandat.litbang.depkes.go.id/riset-badan-litbangkes/menu-riskesnas/menu-riskesdas/374-rkd-2013 (accessed August 20, 2018).
- Jannoo Z, Wah YB, Lazim AM, Hassali MA. Examining diabetes distress, medication adherence, diabetes self-care activities, diabetes-specific quality of life and health-related quality of life among type 2 diabetes mellitus patients. J Clin Transl Endocrinol 2017;9:48–54. doi:10.1016/j.jcte.2017.07.003.
- Cummings DM, Lutes LD, Littlewood K, Solar C, Hambidge B, Gatlin P. Impact of Distress Reduction on Behavioral Correlates and A1C in African American Women with Uncontrolled Type 2 Diabetes: Results from EMPOWER. Ethn Dis 2017;27:155–60. doi:10.18865/ed.27.2.155.
- Polonsky, W.H., Fisher, L., Earles, J. E Al. Assessing Psychosocial Distress in Diabetes. Diabetes Care 2005;28:626–31.
- Fisher L, Glasgow RE, Strycker LA. The relationship between diabetes distress and clinical depression with glycemic control among patients with type 2 diabetes. Diabetes Care 2010;33:1034–6. doi:10.2337/dc09-2175.
- Ehrmann D, Kulzer B, Haak T, Hermanns N. Longitudinal relationship of diabetes-related distress and depressive symptoms: analyzing incidence and persistence. Diabet Med 2015;32:1264– 71. doi:10.1111/dme.12861.
- Chew BH, Mukhtar F, Sherina MS, Paimin F, Hassan NH, Jamaludin NK. The reliability and validity of the Malay version 17-item Diabetes Distress Scale. Malaysian Fam Physician Off J Acad Fam Physicians Malaysia 2015;10:22–35.
- Aljuaid MO, Almutairi AM, Assiri MA, Almalki DM, Alswat K. Diabetes-Related Distress Assessment among Type 2 Diabetes Patients. J Diabetes Res 2018;2018:7328128. doi:10.1155/2018/7328128.
- Farm BAS, Perwitasari DA, Thobari JA, Cao Q, Krabbe PFM, Postma MJ. Translation, Revision, and Validation of the Diabetes Distress Scale for Indonesian Type 2 Diabetic Outpatients with Various Types of Complications. Value Heal Reg Issues 2017;12:63–73. doi:10.1016/j.vhri.2017.03.010.
- Fisher L, Hessler DM, Polonsky WH, Mullan J. When is diabetes distress clinically meaningful?: establishing cut points for the Diabetes Distress Scale. Diabetes Care 2012;35:259–64. doi:10.2337/dc11-1572.
- Faulenbach M, Uthoff H, Schwegler K, Spinas GA, Schmid C, Wiesli P. Effect of psychological stress on glucose control in patients with Type 2 diabetes. Diabet Med 2012;29:128–31. doi:10.1111/j.1464-5491.2011.03431.x.
- Wiesli P, Schmid C, Kerwer O, Nigg-Koch C, Klaghofer R, Seifert B, et al. Acute psychological stress affects glucose concentrations in patients with type 1 diabetes following food intake but not in the fasting state. Diabetes Care 2005;28:1910–5.
- van Son J, Nyklicek I, Pop VJ, Blonk MC, Erdtsieck RJ, Pouwer F. Mindfulness-based cognitive therapy for people with diabetes and emotional problems: long-term follow-up findings from the DiaMind randomized controlled trial. J Psychosom Res 2014;77:81–4. doi:10.1016/j.jpsychores.2014.03.013.
- Chew BH, Vos RC, Metzendorf M-I, Scholten RJ, Rutten GE. Psychological interventions for diabetes-related distress in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2017;9:CD011469. doi:10.1002/14651858.CD011469.pub2.
- Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression. Cochrane Database Syst Rev 2012;12:CD008381. doi:10.1002/14651858.CD008381.pub2.
- A Review of Current Treatment for Triple-negative Breast Cancer (Tnbc)
Abstract Views :82 |
PDF Views:0
Authors
Affiliations
1 1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor,, ID
2 Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Jatinangor,, ID
3 Department of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Universitas Halu Oleo, Kendari,, ID
1 1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor,, ID
2 Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Jatinangor,, ID
3 Department of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Universitas Halu Oleo, Kendari,, ID
Source
Research Journal of Pharmacy and Technology, Vol 15, No 1 (2022), Pagination: 409-418Abstract
We reviewed about the Triple-negative breast cancer (TNBC) and its treatment. We collected credible data from scientific database such as google scholar and Pubmed from published literatures between 2015 to 2020. According the collected literature, TNBC is one of breast cancer type can be found in women with breast cancer. It estimated about 170.000 of TNBC cases worldwide. The ER-/PR-/HER2- TNBC is the character for TNBC, and it has the poorest prognosis among other breast cancer. The risk factor of TNBC is gender, age, breastfeeding status, and special race such as African-American and Hispanic. Besides, the BRCA-1 mutation is related to TNBC. The treatment of TNBC is including surgery and radiotherapy, chemotherapy, and targeted therapy. The surgery, including BCS (Breast-conserving surgery) or called as lumpectomy and mastectomy; chemotherapy agent sensitive to TBNC, including alkylator agents, anthracyclines, taxanes, platinum-based chemotherapy, vinca alkaloids, and antimetabolites; as well targeted therapy such as PARP1 and PARP2 inhibitor, CDK (Cyclin-dependent kinase) inhibitor, p%3 inhibitor, CHK1 inhibitor, androgen antagonist, DNMT1 (DNA Methyltransferase 1) inhibitor, Anti-EGFR, PI3K/AKT/mTOR inhibitor, and anti-VEGF. These treatments are used both in early and metastatic stage of TNBC, alone or in combination.Keywords
Breast cancer, Triple-negative breast cancer, Chemotherapy, Targeted therapy.References
- Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various Types and Management of Breast Cancer: An Overview. J Adv Pharm Technol Res. 2010 Apr-Jun; 1(2): 109–126.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin 2018;68:394–424.
- Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol. 2014 Aug 10; 5(3): 283–298.
- Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, Shi W, Jiang J, Yao PP, Zhu HP. Risk Factors and Preventions of Breast Cancer. Int J Biol Sci. 2017; 13(11): 1387–1397.
- Aysola K, Desai A, Welch C, Xu J, Qin Y, Reddy V, Matthews R, Owens C, Okoli J, Beech DJ, Piyathilake CJ, Reddy SP, Rao VN. Triple Negative Breast Cancer – An Overview. Hereditary Genet. 2013; 2013(Suppl 2): 001.
- Mehanna J, Haddad FGH, Eid R, Lambertini M, Kourie HR. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. Int J Womens Health. 2019; 11: 431–437.
- De Rujiter TC, Veeck J, de Hoon JPJ, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011 Feb; 137(2):183-192.
- Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016 Jun 16;11(6):e0157368.
- Ma H, Ursin G, Xu X, Lee E, Togawa K, Duan L, Lu Y, Maloon KE, Marchbanks PA, McDonald JA, Simon MS, Folger SG, Sullivan-Halley J, Deapen DM, Press MF, Bernstein L. Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. Breast Cancer Research. 2017; 19(6):1-14
- Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D, Villarreal-Garza C, González-Angulo AM, Bargalló E, Aguilar JL, Mohar A, Arrieta Ó. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011 Aug 15;117(16):3658-69.
- Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE. Risk Factors for Triple-Negative Breast Cancer in Women Under Age 45. Cancer Epidemiol Biomarkers Prev. 2009 Apr; 18(4): 1157–1166.
- Gadi VK, Davidson NE. Practical Approach to Triple-Negative Breast Cancer. Journal of Oncology Practice. 2017; 13(5): 293-300
- Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019; 30: 1194–1220.
- Cardoso F, Senkus F, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Lopez BA, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology 29: 1634–1657.
- Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015 Jun; 12(2): 106–116.
- Fajdic J, Djurovic D, Gotovac N, Hrgovic. Criteria and Procedures for Breast Conserving Surgery. Acta Inform Med. 2013 Mar; 21(1): 16–19.
- Rahman GA. Breast Conserving Therapy: A surgical Technique where Little can Mean More. J Surg Tech Case Rep. 2011 Jan-Jun; 3(1): 1–4.
- Kim K, Park HJ, Shin KH, Kim JH, Choi DH, Park W, Ahn SD, Kim SS, Kim JH, Kim J. Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23. Cancer Res Treat. 2018 Oct; 50(4): 1316–1323.
- Wang SE, Sun YD, Zhao SJ, Wei F, Yang G. Breast conserving surgery (BCS) with adjuvant radiation therapy showed improved prognosis compared with mastectomy for early staged triple negative breast cancer patients Running title: BCS had better prognosis than mastectomy for early TNBC patients. Math Biosci Eng. 2019 Sep 26;17(1):92-104. 2
- Lubis AF. 2019. Farmakoterapi Penyakit Kanker. WR Publishing: Yogyakarta.
- Ralhan R, Kaur J. Alkylating agents and cancer therapy. Expert Opin. Ther. Patents. 2007; 17(9): 1061-1075.
- Shimada K, Ishikawa T, Kita K, Narui K, Sugae S, Shimizu D, Tanabe M, Sasaki T, Chishima T, Ichikawa Y, Endo I. Neoadjuvant Docetaxel/Cyclophosphamide in Triple-negative Breast Cancer: Predictive Value of Class III-β Tubulin and Non-basal Subtype. ANTICANCER RESEARCH. 2015; 35: 907-912.
- Halim A, Wahba H. Cisplatin-ifosfamide combination chemotherapy in metastatic triple-negative, anthracycline- and taxane-pretreated breast cancer patients; a phase II study. J BUON. 2012 Apr-Jun;17(2):254-8.
- Chen TC, Cho HY, Wang W, Barath M, Sharma N, Hofman FM, Schönthal AH. A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo. Mol Cancer Ther. 2014 May;13(5):1181-93.
- Narui K, Ishikawa T, Shimizu D, Yamada A, Tanabe M, Sasaki T, Oba MS, Morita S, Nawata S, Kida K, Mogaki M, Doi T, Tsugawa K, Ogata H, Ota T, Kosaka Y, Sengoku N, Kuranami M, Niikura N, Saito Y, Suzuki Y, Suto A, Arioka H, Chishima T, Ichikawa Y, Endo I, Tokuda Y. Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. Breast. 2019 Oct;47:1-9.
- Pandy JGP, Balolong-Garcia JC, Cruz-Ordinario MVB, Que FVF. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review. BMC Cancer. 2019; 19:1-9.
- Mustacchi G, De Laurentiis M. The role of taxanes in triple-negative breast cancer: literature review. Drug Des Devel Ther. 2015; 9: 4303–4318.
- Kaya V, Yildirim M, Yazici G, Gunduz S, Bozcuk H, Paydas S. Effectiveness of Platinum-Based Treatment for Triple Negative Metastatic Breast Cancer: a Meta-Analysis. Asian Pac J Cancer Prev. 2018; 19(5): 1169–1173.
- Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE. Platinum-based chemotherapy in triple-negative breast cancer. Annals of Oncology. 2008; 9(11):1847-1852. 30. Cerrito MG, De Giorgi M, Pelizzoni D, Bonomo SM, Digiacomo N, Scagliotti A, Bugarin C, Gaipa G, Grassilli E, Lavitrano M, Giovannoni R, Bidoli P, Cazzaniga ME. Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. Oncotarget. 2018 Jun 8; 9(44): 27448–27459.
- Li M, Fan Y, Li Q, Zhang P, Yuan P, Ma F, Wang J, Luo Y, Cai R, Chen S, Li Q, Xu B. Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment. Medicine (Baltimore). 2015 Oct; 94(43): e1928.
- O’Reilly EA, Gubbins L, Sharma S, Tully R, Guang MHZ, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell M, McCann A. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clinical. 2015; 3:257-275.
- Ozkan M, Berk V, Kaplan MA, Benekli M, Coskun U, Bilici A, Gumus M, Alkis N, Dane F, Ozdemir NY, Colak D, Dikilitas M. Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience. Neoplasma. 2012;59(1):38-42.
- Koshy N, Quispe D, Shi R, Mansour R, Burton GV. Cisplatin–gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. The Breast. 2010; 19(3):246-248.
- Li Y, Zhou Y, Mao F, Lin Y, Zhang X, Shen S, Sun Q. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis. Breast Cancer Res Treat. 2020 Feb;179(3):533-542.
- Liang X, Di L, Song G, Yan Y, Wang C, Jiang H, Li H. Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer. Chin J Cancer Res. 2014 Oct; 26(5): 550–557.
- Wei CW, Yu YL, Chen YH, Hung YT, Yiang GT. Anticancer effects of methotrexate in combination with α-tocopherol and α-tocopherol succinate on triple-negative breast cancer. Oncol Rep. 2019 Mar;41(3):2060-2066.
- El Kady MS, El Nasr K, Osman MAM, Ellithy M. Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: A phase III study. Journal of Clinical Oncology. 2015; 33 (15_suppl): e12087-e12087.
- Nicolas E, Bertucci F, Sebatier R, Gonçalves A. Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives? Cancers (Basel). 2018 Dec; 10(12): 506.
- Jhan JR, Andrechek ER. Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics. 2017 Nov; 18(17): 1595–1609.
- Chen H, Wu J, Zhang Z, Tang Y, Li X, Liu S, Cao S, Li X. Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis. Front Pharmacol. 2018; 9: 909.
- Dziadkowiec KN, Gasiorowska E, Nowak-Markwitz E, Jankowska A. PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Prz Menopauzalny. 2016 Dec; 15(4): 215–219.
- Exman P, Barroso-Sousa R, Tolaney SM. Evidence to date: talazoparib in the treatment of breast cancer. Onco Targets Ther. 2019 Jul 2;12:5177-5187.
- Guo XX, Wu HL, Shi HY, Su L, Zhang X. The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Manag Res. 2018 Aug 10;10:2553-2562.
- Caulfiled SE, Davis CE, Byers KF. Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation. J Adv Pract Oncol. 2019 Mar;10(2):167-174.
- Wagner LM. Profile of veliparib and its potential in the treatment of solid tumors. OncoTargets and Therapy 2015:8 1931–1939.
- Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Ben-Baruch NE, Werner TL, Cloven NG, Oaknin A, diSilvestro PA, Morgan MA, NAM JH, Leath III CA, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratjczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med 2019; 381:2403-2415.
- McCann KE, Hurvitz SA, McAndrew N. Advances in Targeted Therapies for Triple-Negative Breast Cancer. Drugs. 2019; 79:1217–1230.
- Pernas S, Tolaney SM, Winer EP, Goel S. CDK4/6 inhibition in breast cancer: current practice and future directions. Ther Adv Med Oncol. 2018; 10: 1-15.
- Cretella D, Fumarola C, Bonelli M, Alfieri R, La Monica S, Digiacomo G, Cavazzoni A, Galetti M, Generali D, Petronini PG. Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells. Rep. 2019; 9, 13014.
- Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019 Jul 25;381(4):307-316.
- McCartney A, Moretti E, Sanna G, Pestrin M, Risi E, Malorni L, Biganzoli L, Di Leo A. The role of abemaciclib in treatment of advanced breast cancer. Ther Adv Med Oncol. 2018; 10: 1758835918776925.
- Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2017 Jan 31; 8(5): 8921–8946.
- Synnott NC, McGowan PM, Pierce A, Kiely A, O'Donovan N, Crown J, Kiely PA, Duffy MJ. PRIMA-1MET (APR-246): A novel targeted therapy for triple negative breast cancer?. Journal of Clinical Oncology 2015 33:15_suppl, e12072-e12072.
- Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. European Journal of Cancer. 2017; 83:258-265.
- Bykov VJN, Issaeva N, Zache N, Shilov A, Hulterantz M, Bergman J, Selivanova G, Wiman KG. Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs. J Biol Chem. 2005 Aug 26;280(34):30384-91.
- El Majzoub R, Fayyad-kazan M, El Dine AN, Makki R, Hamade E, Grée R, Hachem A, Talhouk R, Fayyad-kazan H, Badran B. A thiosemicarbazone derivative induces triple negative breast cancer cell apoptosis: possible role of miRNA-125a-5p and miRNA-181a-5p. Genes & Genomics. Genes & genomics. 2019; 41(Suppl 6).
- Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, Stefani C, Lovejoy DB, Sharpe PC, Bernhardt PV, Richardson SR. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem. 2009 Sep 10;52(17):5271-94.
- Bryant C, Rawlinson R, Massey J. Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer. 2014; 14: 570.
- Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, Coinu A, Martorana F, De Santo I, Del Mastro L, De Laurentiis M, Puglisi F, Arpino G. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treat Rev. 2018 Jul;68:102-110.
- Rampurwala M, Wisinski KB, O’Regan R. Role of the Androgen Receptor in Triple-Negative Breast Cancer. Clin Adv Hematol Oncol. 2016 Mar; 14(3): 186–193
- Mina A, Yoder R, Sharma P. Targeting the androgen receptor in triple-negative breast cancer: current perspectives. Onco Targets Ther. 2017 Sep 20;10:4675-4685.
- Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA; Translational Breast Cancer Research Consortium (TBCRC 011). Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013 Oct 1;19(19):5505-12.
- Yu J, Qin B, Moyer AM, Nowsheen S, Liu T, Qin S, Zhuang Y, Liu D, Lu SW, Kalari KR, Visscher DW, Copland JA, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Lou Z, Suman VJ, Weinshilboum R, Boughey JC, Goetz MP, Wang L. Targeting DNA methylation for treating triple-negative breast cancer. Pharmacogenomics. 2019 Nov; 20(16): 1151–1157.
- Mathe A, Wong-Brown M, Locke WJ, Stirzaker C, Braye SG, Forbes JF, Clark SJ, Avery-Kiejda KA, Scott RJ. DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients. Sci Rep. 2016, 6(33435).
- Butler C, Sprowls S, Szalai G, Arsiwala T, Saralkar P, Straight B, Hatcher S, Tyree E, Yost M, Kohler WJ, Wolff B, Putnam E, Lockman P, Liu T. Hypomethylating Agent Azacitidine Is Effective in Treating Brain Metastasis Triple-Negative Breast Cancer Through Regulation of DNA Methylation of Keratin 18 Gene. Transl Oncol. 2020 May 11;13(6):100775.
- Thakur V, Kutty RV. Recent advances in nanotheranostics for triple negative breast cancer treatment. J Exp Clin Cancer Res. 2019; 38(430): 1-22
- Nakai K, Hung MC, Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016; 6(8): 1609–1623
- El Guerran A, Bamdad M, Bignon YJ, Penault-Llorca F, Aubel C. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells. Sci Rep. 2020; 10(6367).
- Bao B, Mitrea C, Wijesinghe P, Marchetti L, Girsch E, Farr RL, Boerner JL, Mohammad R, Dyson G, Terlecky SR, Bollig-Fischer A. Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity. Sci Rep. 2017 Mar 10;7:44125.
- Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart M, Harbeck N. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2012 Aug;134(3):1149-59. .
- Liao WS, Ho Y, Lin YW, Naveen Raj E, Liu KK, Chen C, Zhou XZ, Lu KP, Chao JI. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite. Acta Biomater. 2019 Mar 1;86:395-405.
- Battaglin F, Dadduzio V, Bergamo F, Manai C, Schirripa M, Lonardi S, Zagonel V, Loupakis F. Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. Expert Opin Biol Ther. 2017 Oct;17(10):1297-1308.
- Bouché O, Abdelghani MB, Labourey JL, Triby S, Bensadoun RJ, Jouary T, Guetz GD. Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer. World J Gastroenterol. 2019 Aug 7; 25(29): 4007–4018.
- Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez H, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Luci A, DeSynder SM, Tripathy D, Valero V, Ueno NT. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018;4(9):1207-1213.
- Lee JJX, Loh K, Yap YS. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med. 2015 Dec; 12(4): 342–354.
- Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. 2018 Jun;169(3):397-406.
- Ribbati D, Nico B, Ruggieri S, Tamma R, Simone G, Mangia A. Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer. Transl Oncol. 2016 Oct; 9(5): 453–457.
- Dent SF. The role of VEGF in triple-negative breast cancer: where do we go from here? Annals of Oncology. 2009; 20: 1615–1617.
- Greenberg S, Rugo HS. Triple-negative breast cancer: role of antiangiogenic agents. Cancer J. 2010 Jan-Feb;16(1):33-8.
- Manso L, Moreno F, Márquez R, Castelo B, Arcediano A, Arroyo M, Ballesteros AI, Calvo I, Echarri MJ, Enrech S, Gómez A, González Del Val R, López-Miranda E, Martín-Angulo M, Martínez-Jañez N, Olier C, Zamora P. Use of bevacizumab as a first-line treatment for metastatic breast cancer. Curr Oncol. 2015 Apr;22(2):e51-60.
- Gui X, Li H, Song G, Shao B, Jiang H. Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall: A case report. Medicine (Baltimore). 2018 Nov;97(48):e13410.
- Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, McDermott EW, Evoy D, Pierce A, O’Donovan N, Crown J, Duffy MJ. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol. 2011 Oct;22(10):2234-40.
- Lou L, Yu Z, Wang Y, Wang S, Zhao Y. c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo. Cancer Sci. 2018 May;109(5):1648-1659.
- Finn RS, Bengala C, Ibrahim N, Roché H, Sparano J, Strauss LC, Fairchild J, Sy O, Goldstein LJ. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res. 2011 Nov 1;17(21):6905-13.
- Tian J, Raffa FA, Dai M, Moamer A, Khadang B, Hachim IY, Bakdounes K, Ali S, Jean-Claude B, Lebrun JJ. Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells. Br J Cancer. 2018 Dec;119(12):1495-1507.
- The Future Prospective: Potential Magnesium and Calcium for Detracting Side Effect Cisplatin
Abstract Views :75 |
PDF Views:0
Authors
Syafika Alaydrus
1,
Ajeng Diantini
1,
Riezki Amalia
1,
Sriwidodo
2,
Anis Yohana Chaerunisa
2,
Nasrul Wathoni
2
Affiliations
1 Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, West Java 45363,, ID
2 Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, West Java 45363, ID
1 Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, West Java 45363,, ID
2 Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, West Java 45363, ID
Source
Research Journal of Pharmacy and Technology, Vol 15, No 1 (2022), Pagination: 481-488Abstract
Cancer has been caused by more death globally and is associated with magnesium and calcium intake with some cancers. Some studies are shown as a protective agent against chemotherapy-induced nephrotoxicity and neurotoxicity. Despite magnesium and calcium are the opposite in inflammation, reabsorption regulation, and other physiological processes. However, it is important to maintain the balance between magnesium and calcium related to the micronutrients' physiological functions. One of the cancer drugs can lead to hypomagnesemia and hypocalcemia electrolytes such as cisplatin. The purpose of this article is to review the cisplatin mechanism in electrolyte disorder and the association between potential magnesium and calcium for therapy of some cancer.Keywords
Magnesium, Calcium, Cancer, Cisplatin.References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians. 2018;68(6):394-424.
- Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA: a Cancer Journal for Clinicians. 2019;69(5):363-385.
- Malvezzi M, Carioli G, Bertuccio P, et al. Reply to the letter to the editor ‘European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al’by Marsden and Hamoda, On behalf of the British Menopause Society Medical Advisory Council. Annals of Oncology. 2019;30(8):1394-1394.
- Castiglioni S, Maier JA. Magnesium and cancer: a dangerous liason. Magnesium Research. 2011;24(3):92-100.
- Demir C, Demir H, Esen R, Sehitogullari A, Atmaca M, Alay M. Altered Serum Levels of Elements in Acute Leukemia Cases in Turkey. Asian Pacific Journal of Cancer Prevention : APJCP. 2011;12(12):3471-3474.
- Dai Q, Motley S, Smith J, et al. Blood Magnesium, and the Interaction with Calcium, on the Risk of High-Grade Prostate Cancer. PloS one. 2011;6(4):e18237-e18237.
- Peterlik M, Cross H. Vitamin D and calcium insufficiency-related chronic diseases: molecular and cellular pathophysiology. European Journal of Clinical Nutrition. 2009;63(12):1377-1386.
- Tao M-H, Dai Q, Millen A, et al. Associations of intakes of magnesium and calcium and survival among women with breast cancer: Results from Western New York Exposures and Breast Cancer (WEB) Study. American Journal of Cancer Research. 2015;6(1):105-113.
- Alfarouk KO, Stock C-M, Taylor S, et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell International. 2015;15(1):71.
- Karale PA, Karale MA, Utikar MC. Advanced Molecular Targeted Therapy in Breast Cancer. Research Journal of Pharmacology and Pharmacodynamics. 2018;10(1):29-37.
- Makimoto A, Matsui M, Chin M, et al. Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: A protocol for a randomized phase 2 trial. Contemporary Clinical Trials Communications. 2019;16:100440.
- Mavichak V, Wong NL, Quamme GA, Magil AB, Sutton RA, Dirks JH. Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney International. 1985;28(6):914-921.
- Mirmalek S, Jangholi E, Jafari M, et al. comparison of in Vitro Cytotoxicity and Apoptogenic Activity of Magnesium Chloride and Cisplatin as Conventional Chemotherapeutic Agents in the MCF-7 Cell Line. Asian Pacific Journal of Cancer Prevention: APJCP. 2016;17(S3):131-134.
- Sharma BK. Synthetic and Natural Compounds as Anti-Cancer Agents-A Review. Asian Journal of Research in Chemistry. 2017;10(5):699-707.
- Suberu JO, Romero‐Canelón I, Sullivan N, Lapkin AA, Barker GC. Comparative cytotoxicity of artemisinin and cisplatin and their interactions with chlorogenic acids in MCF7 breast cancer cells. ChemMedChem. 2014;9(12):2791-2797.
- Lajer H, Kristensen M, Hansen H, Christensen S, Jonassen T, Daugaard G. Magnesium and potassium homeostasis during cisplatin treatment. Cancer Chemotherapy and Pharmacology. 2005;55(3):231-236.
- Gröber U, Schmidt J, Kisters K. Magnesium in prevention and therapy. Nutrients. 2015;7(9):8199-8226.
- Kisters K, Gröber U. Magnesium and thiazide diuretics. Magnesium Research. 2018;31(4):143-145.
- Jeroen H. Baaij, de.; Joost, G.; Hoenderop, J.; Rene. JM Bindels. Magnesium in man–implication for health and disease. Physiol Rev. 2015;95(1):1-46.
- Mendes P, Bezerra D, Santos L, et al. Magnesium in Breast Cancer: What Is Its Influence on the Progression of This Disease? Biological Trace Element Research. 2017;184(3):334-339.
- Cao L, Joshi P, Sumoza D. Renal salt-wasting syndrome in a patient with cisplatin-induced hyponatremia: case report. American Journal of Clinical Oncology. 2002;25(4):344-346.
- Gums J. Magnesium in cardiovascular and other disorders. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2004;61:1569-1576.
- Günther T. Comment on the number of Mg2+-activated enzymes. Magnesium research : official organ of the International Society for the Development of Research on Magnesium. 2008;21:185-187.
- Goltzman D, Mannstadt M, Marcocci C. Physiology of the calcium-parathyroid hormone-vitamin D axis. Vitamin D in Clinical Medicine. Vol 50: Karger Publishers; 2018:1-13.
- Vakiti A, Mewawalla P. Malignancy-Related Hypercalcemia. StatPearls [Internet]: StatPearls Publishing; 2019.
- Wolf FI, Trapani V. Magnesium and its transporters in cancer: a novel paradigm in tumour development. Clinical Science. 2012;123(7):417-427.
- Ryazanova L, Rondon L, Zierler S, et al. TRPM7 is essential for Mg homeostasis in mammals. Nature Communications. 2010;1:109-109.
- Woudenberg-Vrenken TE, Sukinta A, Van Der Kemp AW, Bindels RJ, Hoenderop JG. Transient receptor potential melastatin 6 knockout mice are lethal whereas heterozygous deletion results in mild hypomagnesemia. Nephron Physiology. 2011;117(2):p11-p19.
- Duan J, Li Z, Li J, et al. Structure of the mammalian TRPM7, a magnesium channel required during embryonic development. Proceedings of the National Academy of Sciences. 2018;115(35):E8201-E8210.
- Jin J, Wu L-J, Jun J, et al. The channel kinase, TRPM7, is required for early embryonic development. Proceedings of the National Academy of Sciences. 2012;109(5):E225-E233.
- Rondón LJ, Groenestege WMT, Rayssiguier Y, Mazur A. Relationship between low magnesium status and TRPM6 expression in the kidney and large intestine. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2008.
- Alexander RT, Hoenderop JG, Bindels RJ. Molecular determinants of magnesium homeostasis: insights from human disease. Journal of the American Society of Nephrology. 2008;19(8):1451-1458.
- Chubanov V, Mittermeier L, Gudermann T. Role of kinase-coupled TRP channels in mineral homeostasis. Pharmacology and Therapeutics. 2018;184:159-176.
- Chubanov V, Waldegger S, y Schnitzler MM, et al. Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. Proceedings of the National Academy of Sciences. 2004;101(9):2894-2899.
- Li M, Du J, Jiang J, et al. Molecular determinants of Mg2+ and Ca2+ permeability and pH sensitivity in TRPM6 and TRPM7. Journal of Biological Chemistry. 2007;282(35):25817-25830.
- Voets T, Nilius B, Hoefs S, et al. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. Journal of Biological Chemistry. 2004;279(1):19-25.
- Long S, Romani AM. Role of Cellular Magnesium in human diseases. Austin Journal of Nutrition and Food Sciences. 2014;2(10).
- Schlingmann KP, Weber S, Peters M, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nature Genetics. 2002;31(2):166-170.
- Zou Z-G, Rios FJ, Montezano AC, Touyz RM. TRPM7, magnesium, and signaling. International Journal of Molecular Sciences. 2019;20(8):1877.
- Schmitz C, Perraud A-L, Johnson C, et al. Regulation of Vertebrate Cellular Mg2+ Homeostasis by TRPM7. Cell. 2003;114:191-200.
- Goytain A, Quamme GA. Identification and characterization of a novel mammalian Mg 2+ transporter with channel-like properties. BMC Genomics. 2005;6(1):48.
- Ryazanova LV, Rondon LJ, Zierler S, et al. TRPM7 is essential for Mg 2+ homeostasis in mammals. Nature Communications. 2010;1(1):1-9.
- Sahni J, Tamura R, Sweet IR, Scharenberg AM. TRPM7 regulates quiescent/proliferative metabolic transitions in lymphocytes. Cell Cycle. 2010;9(17):3565-3574.
- Zierler S, Yao G, Zhang Z, et al. Waixenicin A Inhibits Cell Proliferation through Magnesium-dependent Block of Transient Receptor Potential Melastatin 7 (TRPM7) Channels. The Journal of Biological Chemistry. 2011;286:39328-39335.
- Hanano T, Hara Y, Shi J, et al. Involvement of TRPM7 in Cell Growth as a Spontaneously Activated Ca2+ Entry Pathway in Human Retinoblastoma Cells. Journal of Pharmacological Sciences. 2004;95(4):403-419.
- Yee NS, Zhou W, Liang IC. Transient receptor potential ion channel Trpm7 regulates exocrine pancreatic epithelial proliferation by Mg2+-sensitive Socs3a signaling in development and cancer. Disease Models and Mechanisms. 2011;4(2):240 LP-254.
- Guilbert A, Gautier M, Dhennin-Duthille I, Haren N, Sevestre H, Ouadid-Ahidouch H. Evidence that TRPM7 is required for breast cancer cell proliferation. American Journal of Physiology. Cell physiology. 2009;297:C493-502.
- Kim BJ, Park EJ, Lee JH, Jeon J-H, Kim SJ, So I. Suppression of transient receptor potential melastatin 7 channel induces cell death in gastric cancer. Cancer Science. 2008;99(12):2502-2509.
- Jiang J, Li M, Inoue K, Chu X-P, Seeds J, Xiong Z-G. Transient Receptor Potential Melastatin 7 like Current in Human Head and Neck Carcinoma Cells: Role in Cell Proliferation. Cancer Research. 2007;67:10929-10938.
- Abed E, Moreau R. Importance of melastatin‐like transient receptor potential 7 and cations (Magnesium, calcium) in human osteoblast‐like cell proliferation. Cell Proliferation. 2007;40(6):849-865.
- Gao H, Chen X, Du X, Guan B, Liu Y, Zhang H. EGF enhances the migration of cancer cells by up-regulation of TRPM7. Cell calcium. 2011;50(6):559-568.
- Park HS, Hong C, Kim BJ, So I. The pathophysiologic roles of TRPM7 channel. The Korean Journal of Physiology and Pharmacology. 2014;18(1):15-23.
- Davis FM, Azimi I, Faville RA, et al. Induction of epithelial–mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent. Oncogene. 2014;33(18):2307.
- Desai BN, Krapivinsky G, Navarro B, et al. Cleavage of TRPM7 releases the kinase domain from the ion channel and regulates its participation in Fas-induced apoptosis. Developmental Cell. 2012;22(6):1149-1162.
- Faouzi M, Kilch T, Horgen FD, Fleig A, Penner R. The TRPM7 channel kinase regulates store‐operated calcium entry. The Journal of Physiology. 2017;595(10):3165-3180.
- Cai N, Bai Z, Nanda V, Runnels LW. Mass spectrometric analysis of TRPM6 and TRPM7 phosphorylation reveals regulatory mechanisms of the channel-kinases. Scientific reports. 2017;7:42739.
- Beesetty P, Wieczerzak KB, Gibson JN, et al. Inactivation of TRPM7 kinase in mice results in enlarged spleens, reduced T-cell proliferation and diminished store-operated calcium entry. Scientific Reports. 2018;8(1):1-22.
- Roskoski Jr R. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacological Research. 2015;94:9-25.
- Mikoshiba K. IP3 receptor/Ca2+ channel: from discovery to new signaling concepts. Journal of Neurochemistry. 2007;102(5):1426-1446.
- Izzedine H, Perazella MA. Adverse kidney effects of epidermal growth factor receptor inhibitors. Nephrology Dialysis Transplantation. 2017;32(7):1089-1097.
- Bastidas AC, Deal MS, Steichen JM, Guo Y, Wu J, Taylor SS. Phosphoryl transfer by protein kinase A is captured in a crystal lattice. Journal of the American Chemical Society. 2013;135(12):4788-4798.
- Wesselink E, Kok DE, Bours MJ, et al. Vitamin D, magnesium, calcium, and their interaction in relation to colorectal cancer recurrence and all-cause mortality. The American Journal of Clinical Nutrition. 2020;111(5):1007-1017.
- Wolf FI, Cittadini AR, Maier JA. Magnesium and tumors: ally or foe? Cancer treatment reviews. 2009;35(4):378-382.
- Atoe K, Idemudia J, Eboreime O. Serum Magnesium Levels in Women with Breast Cancer in Benin City, Nigeria. Nigeria Science Domain International. 2014;4(6):723-728.
- Wesselink E, Winkels RM, Van Baar H, et al. Dietary intake of magnesium or calcium and chemotherapy-induced peripheral neuropathy in colorectal cancer patients. Nutrients. 2018;10(4):398.
- Huang W-Q, Long W-Q, Mo X-F, et al. Direct and indirect associations between dietary magnesium intake and breast cancer risk. Scientific Reports. 2019;9:1-10.
- Wark P, Lau R, Norat T, Kampman E. Magnesium intake and colorectal tumor risk: A case-control study and meta-analysis. The American Journal of Clinical Nutrition. 2012;96:622-631.
- Dibaba D, Xun P, Yokota K, White E, He K. Magnesium intake and incidence of pancreatic cancer: the VITamins and Lifestyle study. British Journal of Cancer. 2015;113(11):1615-1621.
- Yang C-Y, Chiu H-F, Tsai S-S, Cheng M-F, Lin M-C, Sung F-C. Calcium and magnesium in drinking water and risk of death from prostate cancer. Journal of Toxicology and Environmental Health Part A. 2000;60(1):17-26.
- Muka T, Kraja B, Ruiter R, et al. Dietary mineral intake and lung cancer risk: the Rotterdam Study. European Journal of Nutrition. 2016;56.
- Arunkumar P, Mukund H, Radheshyam N, Belliyappa M. Clinical evaluation of cisplatin induced nephrotoxicity characterized by electrolyte disturbances. Asian Journal of Research in Pharmaceutical Science. 2011;1(4):100-104.
- Benoehr P, Krueth P, Bokemeyer C, Grenz A, Osswald H, Hartmann JT. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial. Journal of the American Society of Nephrology. 2005;16(2):452-458.
- Blachley JD, HILL JB. Renal and electrolyte disturbances associated with cisplatin. Annals of Internal Medicine. 1981;95(5):628-632.
- Hanigan M, Devarajan P. Cisplatin nephrotoxicity: Molecular mechanisms. Cancer Therapy. 2003;1:47-61.
- Hoffmann K, Marten A, Lindel K, et al. Major combined electrolyte deficiency during therapy with low-dose Cisplatin, 5-Fluorouracil and Interferon alpha: report on several cases and review of the literature [ISRCTN62866759]. BMC Cancer. 2006;6(1):1-5.
- Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treatment Reviews. 1999;25(1):47-58.
- Ashrafi F, Haghshenas S, Nematbakhsh M, et al. The Role of Magnesium Supplementation in Cisplatin-induced Nephrotoxicity in a Rat Model: No Nephroprotectant Effect. International Journal of Preventive Medicine. 2012;3(9):637-643.
- Saito Y, Kobayashi M, Yamada T, et al. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity. Supportive Care in Cancer. 2017;25(2):481-487.
- Arany I, Safirstein RL. Cisplatin nephrotoxicity. Seminars in Nephrology. 2003;23(5):460-464.
- Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney International. 2008;73(9):994-1007.
- Anvari K, Seylanian TM, Mirsadraei M. Evaluation of intravenous magnesium supplementation as prophylaxis for cisplatin-induced Hypomagnesemia. 2010.
- Mohammadianpanah M, Omidvari S, Mosalaei A, Ahmadloo N. Cisplatin-induced hypokalemic paralysis. Clinical Therapeutics. 2004;26(8):1320-1323.
- Vincenzi B, Santini D, Tonini G. Biological interaction between anti-epidermal growth factor receptor agent cetuximab and magnesium. Expert Opinion on Pharmacotherapy. 2008;9(8):1267-1269.
- Maliakal P, Ledford A. Electrolyte and protein imbalance following anti-EGFR therapy in cancer patients: A comparative study. ExpErimEntal and thErapEutic mEdicinE. 2010;1(2):307-311.